Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients
The purpose of this study is to determine the effectiveness, safety, tolerability and best dose of Lapatinib (GW572016) in combination with carboplatin and paclitaxel.
Ovarian Epithelial Cancer Stage III|Stage IV Ovarian Cancer|Stage IV Breast Cancer
DRUG: lapatinib (GW572016)|DRUG: Carboplatin|DRUG: Paclitaxel
Toxicity, 1 year
Objective response (PR or CR), 1 year
The MTD was found in the phase I portion of this study to be oral lapatinib 1000 mg per day for each 4 week cycle and paclitaxel 60 mg/m2 weekly x 3 of a 4 week cycle and carboplatin AUC 2 weekly x 3 of a 4 week cycle.